Chronic Lung Disease of Prematurity Terminated Phase 2 Trials for Lucinactant (DB04897)

Also known as: Bronchopulmonary Dysplasia / Dysplasia, Bronchopulmonary / Ventilator lung in newborn / Congenital pulmonary fibrosis

IndicationStatusPhase
DBCOND0044076 (Chronic Lung Disease of Prematurity)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00215540SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.Prevention